Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy

We propose a mathematical model for the growth of cell-cycle-specific dose limiting bone marrow. In an attempt to determine effective methods of treatment without overdestruction of the bone marrow we implement optimal control theory. We design the control functional to maximize both the bone marrow mass and the dose over the treatment interval. Next we show that an optimal control exists for this problem, and then we characterize our optimal control in terms of the solutions to the optimality system, which is the state system coupled with the adjoint system. We show that the optimality system is unique for suitably small time intervals. Finally, we analyze the optimal control and the optimality system using numerical techniques. This allows us to suggest optimal methods of treatment that prevent excessive destruction of the bone marrow based on the specific weights in our objective functional.

[1]  J. M. Murray,et al.  Some optimal control problems in cancer chemotherapy with a toxicity limit. , 1990, Mathematical biosciences.

[2]  Michael C. Mackey,et al.  Unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis , 1978 .

[3]  Martin M. Eisen,et al.  Mathematical Models in Cell Biology and Cancer Chemotherapy , 1979 .

[4]  A Swierniak,et al.  Optimal control problems arising in cell‐cycle‐specific cancer chemotherapy , 1996, Cell proliferation.

[5]  M. Petit.  Dynamic optimization. The calculus of variations and optimal control in economics and management : by Morton I. Kamien and Nancy L. Schwartz. Second Edition. North-Holland (Advanced Textbooks in Economics), Amsterdam and New York, 1991. Pp. xvii+377. ISBN0-444- 01609-0 , 1994 .

[6]  G. F. Webb,et al.  Resonance phenomena in cell population chemotherapy models , 1990 .

[7]  W. Fleming,et al.  Deterministic and Stochastic Optimal Control , 1975 .

[8]  Z. Agur,et al.  A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. , 1992, Mathematical biosciences.

[9]  R. Vidal.  Dynamic optimization: The calculus of variations and optimal control in economics and management: Morton I. KAMIEN and Nancy L. SCHWARTZ Volume 4 in: Dynamic Economics: Theory and Applications, North-Holland, New York, 1981, xi + 331 pages, Dfl.90.00 , 1982 .

[10]  R E Wittes,et al.  Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Hainsworth,et al.  Paclitaxel administered by 1‐hour infusion. Preliminary results of a phase 1/11 trial comparing two schedules , 1994, Cancer.

[12]  J C Panetta,et al.  A mathematical model of breast and ovarian cancer treated with paclitaxel. , 1997, Mathematical biosciences.

[13]  E. Eisenhauer,et al.  Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. , 1993, Cancer treatment reviews.

[14]  C. Lipschultz,et al.  Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.

[15]  G. F. Webb,et al.  Resonances in periodic chemotherapy scheduling , 1995 .

[16]  Zvia Agur,et al.  Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs , 1988 .

[17]  G. W. Swan.  Role of optimal control theory in cancer chemotherapy. , 1990, Mathematical biosciences.

[18]  Morton I. Kamien,et al.  Dynamic Optimization , 2020, Natural Resource Economics.

[19]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[20]  Z. Agur,et al.  The Effect of Drug Schedule on Responsiveness to Chemotherapy a , 1987 .

[21]  J. M. Murray,et al.  Optimal control for a cancer chemotherapy problem with general growth and loss functions. , 1990, Mathematical biosciences.